136 related articles for article (PubMed ID: 1722627)
1. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
Kanimoto Y; Okada K
Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
[TBL] [Abstract][Full Text] [Related]
2. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
Iguchi H; Ikeuchi T; Kai Y; Yoshida H
Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
[TBL] [Abstract][Full Text] [Related]
3. [Application of antiandrogens on prostatic diseases].
Takahashi S; Hasegawa F; Isurugi K
Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
[TBL] [Abstract][Full Text] [Related]
4. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
Umeda K
Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
[TBL] [Abstract][Full Text] [Related]
5. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
6. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
[TBL] [Abstract][Full Text] [Related]
7. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
[TBL] [Abstract][Full Text] [Related]
8. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
McConnell JD
Urol Clin North Am; 1990 Aug; 17(3):661-70. PubMed ID: 1695786
[TBL] [Abstract][Full Text] [Related]
9. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
10. [Fundamental and clinical study of the anti-prostatic effect of allylestrenol].
Yamanaka H; Kosaku N; Makino T; Shida K
Hinyokika Kiyo; 1983 Sep; 29(9):1133-45. PubMed ID: 6203385
[TBL] [Abstract][Full Text] [Related]
11. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].
Noguchi K; Takeda M; Hosaka M; Kubota Y
Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological combinations in the treatment of benign prostatic hypertrophy].
Di Silverio F; D'Eramo G; Flammia GP; Buscarini M; Frascaro E; Mariani M; Sciarra A
J Urol (Paris); 1993; 99(6):316-20. PubMed ID: 7516378
[TBL] [Abstract][Full Text] [Related]
13. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
Murakoshi M; Ikeda R; Fukui N; Nakayama T
Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
15. Medical management of prostatic diseases.
Schlegel PN
Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
[TBL] [Abstract][Full Text] [Related]
16. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
Murakoshi M; Ikada R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy].
Fukuoka H; Ishibashi Y; Shiba T; Tuchiya F; Sakanishi S
Hinyokika Kiyo; 1993 Jul; 39(7):679-83. PubMed ID: 7689782
[TBL] [Abstract][Full Text] [Related]
18. [New conservative therapeutic approaches in benign prostatic hyperplasia].
Schulze H; Berges R; Paschold K; Senge T
Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
[TBL] [Abstract][Full Text] [Related]
19. Benign prostatic hyperplasia. Hormonal treatment.
McConnell JD
Urol Clin North Am; 1995 May; 22(2):387-400. PubMed ID: 7539183
[TBL] [Abstract][Full Text] [Related]
20. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
